You Position: Home > Paper
浅析新普乐可复平稳血药浓度的临床价值
( views:304, downloads:80 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Organ Transplantation
- Issue:
- 12
- DOI:
- No doi available
- Key Word:
- No keyword available
Abstract： 不同个体以及同一个体不同时间对药物均存在较明显的药代动力学和药效学差异.对狭窄治疗指数(NTI)药物而言,这一点尤其重要.早在1985年,就有学者提出需对NTI类药物环孢素A进行血药浓度监测.目前,监测受者NTI血药浓度以优化移植存活结果仍是移植医生关注的重点.为进一步提高血药浓度的稳定性和改善受者依从性,安斯泰来公司开发了每天1次的他克莫司(Tac)缓释剂型(即新普乐可复(R)).免疫抑制剂血药浓度的波动究竟对移植受者有何影响,移植受者使用他克莫司缓释剂后的血药浓度是否更稳定?本文将加以讨论.
- [1]Sańko-Resmer,J.,Thorburn,D.,Boillot,O.,etc.Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: An open-label multicenter study[J].2012,25(3).
- [2]Niioka,T.,Satoh,S.,Kagaya,H.,etc.Comparison of pharmacokinetics and pharmacogenetics of once-and twice-daily tacrolimus in the early stage after renal transplantation[J].2012,94(10).
- [3]Hariharan S,Steinberg S,Alloway R,etc.Conversion of stable kidney transplant recipients from a twice daily prograf-based regimen to a once daily modified release tacrolimus-based regimen.[J].2005,37(2).